Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Verastem raises $100M, plots path forward with targeted cancer combo

The biotech will scale back some commercial operations for Copiktra as it tests a newly acquired pipeline asset

Paul Bonanos, Associate Editor
February 28, 2020 11:49 PM UTC
Updated on Feb 28, 2020 at 11:54 PM UTC

Based on an early peek at clinical data, an investor syndicate is endorsing Verastem’s strategic realignment behind a pipeline combo in a targeted cancer indication. The group is pouring $100 million into the company at a double-digit premium as the biotech pares expenses.

Verastem Oncology Inc. (NASDAQ:VSTM) has identified as a key priority its combination of newly acquired MEK and RAF inhibitor VS-6766 plus FAK inhibitor defactinib to treat K-Ras mutant solid tumors, including low-grade serous ovarian cancer, non-small cell lung cancer (NSCLC) and colorectal cancer...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Verastem Inc.